Streetbeat News

AVDL

Avadel Pharmaceuticals plc

https://www.avadel.com

Industry

Drug Manufacturers - Specialty & Generic

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Open

8.05

Mkt cap

747M

Volume

1.1M

High

8.06

P/E Ratio

-10.33

52-wk high

19.09

Low

7.75

Div yield

N/A

52-wk low

7.39

Biotech stocks, including small caps, experienced a sell-off as the 10-Year Treasury yield rose above 4.75%. The JP Morgan Healthcare event may improve sentiment in the biotech sector. Three biotech/biopharma stocks are highlighted as oversold.

Portfolio Pulse from

January 13, 2025 | 6:15 pm

Avadel Pharmaceuticals' 2025 net sales guidance for Lumryz is below expectations due to patient attrition. The company is working to address these challenges and increase patient uptake. Legal updates have reduced risks, but there was a loss in the idiopathic hypersomnia market.

Portfolio Pulse from

January 12, 2025 | 8:45 am

Avadel Pharmaceuticals has announced preliminary results for 2024, highlighting a significant increase in net revenue from LUMRYZ sales, with a 150% rise to $50 million in Q4 2024 compared to the same period in 2023. The company also reported 2,500 patients on LUMRYZ by the end of 2024.

Portfolio Pulse from

January 08, 2025 | 9:30 pm

Avadel Pharmaceuticals will host a conference call on January 8, 2025, to provide a corporate update and discuss preliminary financial results for Q4 and full year 2024.

Portfolio Pulse from

January 03, 2025 | 1:15 pm

Avadel Pharmaceuticals will participate in a fireside chat at the Jefferies London Healthcare Conference on November 20, 2024.

Portfolio Pulse from

November 13, 2024 | 1:15 pm

Avadel Pharmaceuticals (NASDAQ:AVDL) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included CEO Greg Divis and CFO Tom McHugh, with analysts from Jefferies, Oppenheimer, H.C. Wainwright, Needham, and Piper Sandler attending.

Portfolio Pulse from

November 12, 2024 | 8:30 pm

HC Wainwright & Co. has reiterated its Buy rating for Avadel Pharmaceuticals, maintaining a price target of $27.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 7:57 pm

Oppenheimer analyst Francois Brisebois has maintained an 'Outperform' rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and raised the price target from $29 to $30.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 6:20 pm

Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:15 pm

Tenon Medical, Avadel Pharmaceuticals, and Carvana shares are trading higher due to positive developments. Tenon Medical highlighted successful clinical data, Avadel won a court ruling favoring FDA approval of its drug, and Carvana reported strong Q3 results.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:53 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.